BillionToOne (BLLN)
Develops molecular diagnostics for prenatal screening and cancer treatment selection.
Something off on this page? Send us feedback.
Offers UNITY prenatal genetic tests and Northstar liquid-biopsy oncology assays built on its single-molecule sequencing platform. Revenue comes from commercial diagnostics, with prenatal care established first and oncology expanded afterward.
Uses its smNGS molecular-counting platform to provide prenatal genetics and oncology diagnostics. UNITY began as its first commercial product and expanded within prenatal genetics; Northstar Select became its liquid-biopsy assay for therapy-selection insights in advanced cancer.
The oncology platform has since added Northstar PGx and Northstar Select CH, while Unity Confirm offers non-invasive confirmation after high-risk screening results. Together, these products move the original platform beyond prenatal screening into cancer care.
Based in Menlo Park, it operates commercial diagnostics rather than a pure R&D model. Continued development and expansion depend materially on its co-founders and other key managers.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 2, 2026 | Canaccord Genuity | Target | Target: — | Target: $120 |
| Jun 29, 2026 | Guggenheim | Reiterate | Rating: —Target: $120 | Target: $125 |
| May 7, 2026 | BTIG | Reiterate | Rating: —Target: $140 | Target: $130 |
| Mar 5, 2026 | BTIG | Reiterate | Rating: —Target: $160 | Target: $140 |
| Jan 6, 2026 | Guggenheim | Target | Target: — | Target: $120 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $548.6M · Total debt $143.9M · Total assets $729.7M · Shareholders' equity $536.8M
- Revenue
- $109.4M
- Operating income
- $5.5M
- Net income
- $8.1M
No dividends on record.
| Institutions | ≈ 33.23% | 15.28M shares | |
|---|---|---|---|
| 164 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 0.00% | 700 shares | |
| 1 holder · as of Sep 21, 2026 | |||
| Other | ≈ 66.77% | 30.71M shares | |
| remainder | |||
46.00M company shares as of Aug 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Adams Street Partners LLCInstitution | 3.72% | 1.71M | as of Jun 30, 2026 |
Price T Rowe Associates Inc /MD/Institution | 2.20% | 1.01M | as of Jun 30, 2026 |
Baillie Gifford & CoInstitution | 1.96% | 901,420 | as of Jun 30, 2026 |
Vanguard Portfolio Management LLCInstitution | 1.83% | 840,970 | as of Jun 30, 2026 |
Invesco Ltd.Institution | 1.82% | 835,614 | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 17, 2026 | Thomas P. Lynch | officer: See Remarks | −35,112 | $110.33 |
- Natera
Prenatal cfDNA, carrier screening, and cancer MRD testing
- Labcorp
Prenatal cfDNA and carrier screening through a national lab network
- Quest Diagnostics
Prenatal cfDNA and carrier screening in national diagnostics
- Caris Life Sciences
Molecular profiling for therapy selection and cancer monitoring
- Myriad Genetics
NIPT and carrier screening in women's health
- Guardant Health
Liquid-biopsy profiling and response monitoring in advanced cancer
- Tempus AI
Genomic profiling for therapy selection in oncology
- NeoGenomics
Oncology molecular profiling and liquid-biopsy diagnostic testing
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| BillionToOne | $112.46 | +8.28% | $4.78B | 167.5 | 143.3 | 12.0 | +64.3% |
| Natera | $385.65 | +4.05% | $53.08B | — | — | 19.6 | +37.7% |
| Labcorp | $309.13 | −3.69% | $26.32B | 26.6 | 16.3 | 1.8 | +5.8% |
| Quest Diagnostics | $232.80 | −4.93% | $27.03B | 26.0 | 20.3 | 2.3 | +10.2% |
| Caris Life Sciences | $32.21 | +5.07% | $8.66B | 85.6 | 127.9 | 8.8 | +45.4% |
| Myriad Genetics | $3.97 | −1.12% | $378.7M | — | — | 0.5 | −10.5% |
| Guardant Health | $178.36 | +2.58% | $23.33B | — | — | 19.7 | +44.3% |
| Tempus AI | $78.91 | +1.12% | $13.67B | — | — | 9.5 | +21.6% |
| NeoGenomics | $19.28 | −0.69% | $498.7M | — | 69.3 | 0.7 | +11.2% |
| Median | 26.6 | 44.8 | 5.5 | +16.4% |